Reading Time: 2 minutesIntroduction Allergies and asthma represent significant public health burdens in the United States, disproportionately affecting males due to interplay between genetic predispositions, environmental exposures, and hormonal influences. Jatenzo (testosterone undecanoate), an oral formulation of bioidentical testosterone approved by the FDA for hypogonadism, has garnered attention for its potential off-label immunomodulatory effects in allergic airway diseases. This article synthesizes emerging immunological data, focusing on American males aged 18-65, where late-onset hypogonadism correlates with exacerbated Th2-mediated inflammation. By restoring physiological androgen levels, Jatenzo may attenuate IgE-driven hypersensitivity and bronchial hyperreactivity, offering a novel adjunctive strategy beyond conventional antihistamines, inhaled corticosteroids, and leukotriene … Continue reading →